NADAC acquisition cost data for SIROLIMUS 1 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00904724804 | $4.36 | 2022-12-21 | Rx |
| 16714018801 | $4.36 | 2022-12-21 | Rx |
| 50268071811 | $4.36 | 2022-12-21 | Rx |
| 50268071813 | $4.36 | 2022-12-21 | Rx |
| 55111065301 | $4.36 | 2022-12-21 | Rx |
| 59762100201 | $4.36 | 2022-12-21 | Rx |
| 67877074701 | $4.36 | 2022-12-21 | Rx |
| 68084091525 | $4.36 | 2022-12-21 | Rx |
| 68084091595 | $4.36 | 2022-12-21 | Rx |
| 68462068301 | $4.36 | 2022-12-21 | Rx |
Generic: Sirolimus | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $21.0M | 28,535 | 5,462 | $10.45 |
| 2020 | $23.9M | 32,364 | 6,164 | $10.10 |
| 2021 | $21.3M | 31,750 | 6,199 | $9.04 |
| 2022 | $20.5M | 32,869 | 6,477 | $8.43 |
| 2023 | $22.5M | 36,478 | 7,218 | $8.23 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $2.6M | 4,421 | 922 |
| Florida | $2.1M | 3,301 | 670 |
| Texas | $2.1M | 3,617 | 777 |
| New York | $1.6M | 2,481 | 535 |
| Pennsylvania | $1.4M | 1,852 | 379 |
| Tennessee | $833.8K | 1,171 | 240 |
| Minnesota | $830.4K | 896 | 193 |
| Ohio | $824.9K | 1,418 | 266 |
| Massachusetts | $755.8K | 1,235 | 259 |
| Indiana | $754.2K | 1,283 | 280 |
| Georgia | $608.8K | 945 | 199 |
| Colorado | $602.0K | 946 | 243 |
| Washington | $584.8K | 933 | 207 |
| North Carolina | $560.1K | 867 | 184 |
| Illinois | $524.4K | 960 | 210 |
| Arizona | $506.4K | 1,084 | 236 |
| Michigan | $483.5K | 776 | 170 |
| Wisconsin | $449.2K | 840 | 154 |
| Maryland | $431.8K | 735 | 147 |
| Virginia | $354.4K | 488 | 106 |
| Missouri | $349.1K | 712 | 142 |
| Louisiana | $295.1K | 524 | 93 |
| Kentucky | $275.0K | 383 | 89 |
| Oregon | $272.3K | 442 | 101 |
| Connecticut | $228.2K | 293 | 65 |
| Nebraska | $214.0K | 282 | 54 |
| Alabama | $210.1K | 353 | 68 |
| New Jersey | $201.7K | 391 | 72 |
| Utah | $188.5K | 348 | 80 |
| Oklahoma | $185.9K | 291 | 69 |
| Arkansas | $179.5K | 257 | 48 |
| Iowa | $178.3K | 334 | 50 |
| Mississippi | $126.3K | 162 | 27 |
| Puerto Rico | $114.7K | 290 | 33 |
| Kansas | $102.6K | 151 | 34 |
| South Carolina | $97.5K | 151 | 40 |
| New Mexico | $63.2K | 115 | 23 |
| Idaho | $61.4K | 104 | 24 |
| Hawaii | $49.8K | 78 | 18 |
| Rhode Island | $47.2K | 65 | 12 |
| Nevada | $43.1K | 78 | 27 |
| Delaware | $38.1K | 60 | 11 |
| Montana | $37.6K | 50 | 14 |
| West Virginia | $37.3K | 64 | 14 |
| District of Columbia | $35.0K | 75 | 19 |
| Alaska | $25.5K | 27 | N/A |
| Vermont | $24.6K | 34 | N/A |
| Maine | $16.5K | 42 | N/A |
| Wyoming | $13.2K | 31 | N/A |
| New Hampshire | $12.3K | 24 | N/A |
| South Dakota | $10.6K | 15 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.